Upregulation of maspin expression in human cervical carcinoma cells by transforming growth factor β1 through the convergence of Smad and non-Smad signaling pathways

Oncology Letters
Ariyaphong WongnoppavichKongthawat Chairatvit

Abstract

Mammary serine protease inhibitor (maspin), encoded by the serpin family B member 5 gene, serves as a tumor suppressor through the inhibition of cancer cell invasion and metastasis. Paradoxically, maspin levels are upregulated in a number of types of malignant cells. Therefore, the regulation of maspin expression may depend on the genetic or epigenetic background and the specific microenvironment of carcinoma cells. In the present study, it was demonstrated that transforming growth factor β1 (TGF-β1) induced maspin expression at the transcript and protein levels in the human cervical carcinoma HeLa and human oral squamous carcinoma HSC4 cell lines. The inhibition of the mothers against decapentaplegic homolog (Smad)-dependent pathway by a Smad3-specific inhibitor suppressed maspin induction by TGF-β1 in HeLa cells. Inhibition of the non-Smad pathway by pretreatment with the mitogen-activated protein kinase kinase 1/2 (MEK1/2) inhibitor U0126, or the p38 mitogen-activated protein kinase (p38 MAPK) inhibitor SB202190, attenuated the effect of TGF-β1 on maspin upregulation, whereas pretreatment with pyrrolidine dithiocarbamate (a nuclear factor κB inhibitor), wortmannin (a phosphoinositide 3-kinase inhibitor) or SP600125 (a c-Jun ...Continue Reading

References

Jan 1, 1996·Breast Cancer Research and Treatment·C L ArteagaS D Hurd
Apr 23, 1999·The Journal of Biological Chemistry·C HuangZ Dong
Feb 16, 2002·Methods : a Companion to Methods in Enzymology·K J Livak, T D Schmittgen
Nov 12, 2002·Clinical Breast Cancer·Nicolai MaassWalter Jonat
Jun 6, 2003·Oncogene·Marc M OshiroBernard W Futscher
Feb 7, 2006·Gynecologic Oncology·Stephen L RoseFrederick E Domann
Sep 27, 2006·Journal of Cellular Physiology·Caleb M BaileyMary J C Hendrix
Oct 10, 2006·Cancer Metastasis Reviews·Charles A Dinarello
Jan 20, 2007·Science·Michelangelo CordenonsiStefano Piccolo
Feb 23, 2008·Experimental Eye Research·Mark A HorswillSally S Twining
Jun 3, 2010·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Jeong KimKyu Taek Lee
Feb 19, 2011·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Anna TorresRyszard Maciejewski
Apr 16, 2011·Journal of Mammary Gland Biology and Neoplasia·Yvette Drabsch, Peter ten Dijke
Apr 20, 2011·Laboratory Investigation; a Journal of Technical Methods and Pathology·Brigitte GouletJohn D Lewis
Jun 7, 2011·Cell and Tissue Research·Carl-Henrik Heldin, Aristidis Moustakas
Jun 28, 2011·Cell and Tissue Research·Yabing MuMaréne Landström
May 1, 2012·Journal of Signal Transduction·Rebecca Elston, Gareth J Inman
Jul 4, 2012·Cancer Metastasis Reviews·Thomas M BodenstineMary J C Hendrix

❮ Previous
Next ❯

Datasets Mentioned

BETA
MDA-MB-231

Methods Mentioned

BETA
Protein Assay
Transfection
Assay

Software Mentioned

SPSS

Related Concepts

Related Feeds

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.